Finance

Lists
APNHF:OTCMKTS
Aspen Pharmacare Holdings Ltd
$8.90
0.00%
(0.00) 1D
Aug 14, 2:56:52 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for APNHF...
Mkt. cap
66.95B
Avg. vol.
0.00
Volume
0.00
52-wk high
$8.90
52-wk low
$6.23
Beta
1.43
Shares outstanding
432.92M
No. of employees
9K
Mkt. cap
66.95B
Avg. vol.
0.00
Volume
0.00
52-wk high
$8.90
52-wk low
$6.23
Beta
1.43
Shares outstanding
432.92M
No. of employees
9K
News stories
From web sources and news partners
Profile
Aspen Pharmacare Holdings Limited is a multinational pharmaceutical company headquartered in uMhlanga, South Africa. Founded in 1997, it listed on the Johannesburg Stock Exchange in 1998, and purchased South African Druggists in 1999 before expanding into international markets. The largest pharmaceutical company in Africa through aggressive mergers and expansion, with major manufacturing sites in locations such as Gqeberha in South Africa, Bad Oldesloe in Germany, Notre-Dame-de-Bondeville in France, and Oss, Netherlands, Aspen is known for manufacturing and distributing branded pharmaceuticals as well as generic HIV/AIDS antiretrovirals and cancer medications. Among other products, Aspen has also been involved in manufacturing the Janssen COVID-19 vaccine through "fill and finish", and has the rights to sell the product under its own brand name Aspenovax. The company's revenue in 2022 was R38.6 billion. In 2016, Aspen was fined for high prices on cancer drugs, and after an investigation Aspen committed to reduce prices for five years in the European Union. Wikipedia
About Aspen Pharmacare Holdings Ltd
CEOStephen Saad
Employees9.34K
Founded1850
HeadquartersDurban, KwaZulu-Natal, South Africa
SectorPharmaceutical industry
Previous reportsAll values in ZAR
Loading Previous Earnings...
Revenue
Net income
All values in ZAR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
8.54B
8.54B
8.90B
8.90B
Cost of goods sold
4.81B
4.81B
5.59B
5.59B
Cost of revenue
4.81B
4.81B
5.59B
5.59B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.17B
2.17B
2.16B
2.16B
Operating expense
2.82B
2.82B
3.83B
3.83B
Total operating expenses
7.63B
7.63B
9.42B
9.42B
Operating income
910.00M
910.00M
-528.50M
-528.50M
Other non operating income
-9.50M
-9.50M
24.50M
24.50M
EBT including unusual items
577.50M
577.50M
-786.50M
-786.50M
EBT excluding unusual items
577.50M
577.50M
-786.50M
-786.50M
Income tax expense
144.50M
144.50M
90.50M
90.50M
Effective tax rate
25.02%
25.02%
-11.51%
-11.51%
Other operating expenses
643.50M
643.50M
1.67B
1.67B
Net income
736.00M
736.00M
587.50M
587.50M
Net profit margin
8.62%
8.62%
6.60%
6.60%
Earnings per share
-
-
-
-
Interest and investment income
83.50M
83.50M
83.50M
83.50M
Interest expense
-426.50M
-426.50M
-346.00M
-346.00M
Net interest expenses
-343.00M
-343.00M
-262.50M
-262.50M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.39B
1.39B
-48.00M
-48.00M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google apps